缺血性心脏病是心血管系统疾病最常见的死因.治疗缺血性心脏病的关键就在于促进梗死区域血管生成,改善梗死区血供.冠状动脉旁路移植术(CABG)和经皮冠状动脉腔内成形术(PTCA)是目前应用于临床的治疗冠心病比较成熟的技术,但也有一定的局限性.随着对血管再生微观机制研究的进一步深入,蛋白治疗、细胞治疗和转基因治疗等多种治疗方法均被用于促进心肌血管再生和冠脉侧支循环的建立,从而为缺血心肌提供重要的血供来源.目前把这种促进缺血组织血管再生、改善血供为目的的治疗称为分子搭桥(molecular bypass).

[1] HOEBEN A, LANDUYT B, HIGHLEY M S. Vascular endothelial growth factor and angiogenesis. 2004. doi:10.1124/pr.56.4.3
[2] PALMER-KAZEN U, WAHLBERG E. Arteriogenesis in peripheral arterial disease. 2003(4-5). doi:10.1080/713715232
[3] KIEFER F N, NEYSARI S, HUMAR R. Hypertension and angiogenesis. 2003(21). doi:10.2174/1381612033454540
[4] BANAI S, JAKLITSCH M T, SHOW M. Angiogenic-induced enhancement of collateral blood flow to ischaemic myocardium by vascular endothelial growth factor in dogs, 1994
[5] SIMONS M, ANNEX B H, LAHAM R J. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2:double blind,randomized,controlled clinical trial. 2002(7). doi:10.1161/hc0802.104407
[6] KHAN T A, SELLKE F W, LAHAM R J. Therapeutic angiogenesis for coronary artery disease. 2002(1). doi:10.1007/s11936-002-0027-z
[7] NAMBA T, KOIKE H, MURAKAMI K. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. 2003(18). doi:10.1161/01.CIR.0000093190.53478.78
[8] HAO X, MANSSON-BROBERG A, BLOMBERG P. Angiogenic and cardiac functional effects of dual gene transfer of VEGF-A165 and PDGF-BB after myocardial infarction. 2004(1). doi:10.1016/j.bbrc.2004.07.101
[9] SYMES J F, LOSORDO D W, VALE P R. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease, 1999
[10] KIM E J, LI R K, WEISEL R D. Angiogenesis by endothelial cell transplantation. 2001(5). doi:10.1067/mtc.2001.117623
[11] DAVANI S, DESCHASEAUX F, CHALMERS D. Can stem cells mend a broken heart?. 2005(2). doi:10.1016/j.cardiores.2004.10.037
[12] MURASAWA S, KAWAMOTO A, HORII M. Niche-dependent translineage commitment of endothelial progenitor cells,not cell fusion in general,into myocardial lineage cells, 2005(7)
[13] VASA M, FICHTLSCHERER S, AICHER A. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease, 2001
[14] HILL J M, ZALOS G, HALCOX J P. Circulating endothelial progenitor cells,vascular function,and cardiovascular risk. 2003. doi:10.1056/NEJMoa022287
[15] WOL LERT K C, DREXLER A. Clinical applications of stem cells for the heart. 2005
[16] MESSINA E, de ANGELIS L, FRATI G. Isolation and expansion of adult cardiac stem cells from human and murine heart. 2004. doi:10.1161/01.RES.0000147315.71699.51
[17] YOON Y S, WECKER A, HEYD L. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. 2005(2)
[18] TANG Y L, ZHAO Q, ZHANG Y C. Autologous messenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium, 2004(1)
[19] TAKAHASHI T, KALKA C, MASUDA H. Ischemiaand cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. 1999(4). doi:10.1038/7434
[20] WEISS T W, MEHRABI M R, KAUN C. Prostaglandin E1 induces vascular endothelial growth factor-1 in human adult cardiac myocytes but not in human adult cardiac fibroblasts via a cAMP-dependent mechanism. 2004